Torrent Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+21.4%+7.3%+11.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+22.5%+10.5%+18.5%
+17.6%+14.3%+19.9%
+11.9%+15.4%+33.0%
+13.2%+15.4%+33.0%
+195.6%−0.5%+0.3%
+131.7%+10.7%+10.6%
+16.9%−20.9%+37.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TORNTPHARM₹4,580.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMAJBCHEPHARMMANKINDZYDUSLIFEDIVISLABMAXHEALTHDRREDDYCIPLAMcap ₹1.55L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+11.5+7.3+21.4—
EBITDA Growth—+18.5+10.5+22.5—
EBIT Growth—+19.9+14.3+17.6—
Net Income Growth—+33.0+15.4+11.9—
EPS Growth—+33.0+15.4+13.2—
Total Assets Growth—+0.3-0.5+195.6—
Total Equity Growth—+10.6+10.7+131.7—
Cash from Operations Growth—+37.9-20.9+16.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.